Drug intelligence / Profile preview

B201 acetate

Development stage: Unknown
Lead developer: ApopLogic Pharmaceuticals
Modality: Peptides

Overview

B201 acetate (Breceptin) is a synthetic peptide dimer of a decapeptide developed by ApopLogic Pharmaceuticals for the treatment of various solid tumors. It acts as a dual antagonist of the bradykinin B1 and B2 receptors. By targeting these receptors, which are often overexpressed on cancer cells, the drug directly induces apoptosis (programmed cell death). Additionally, B201 acetate modulates the tumor microenvironment by targeting inflammatory cells and factors that promote tumor growth and metastasis. It has been investigated for several indications, including small cell lung cancer (SCLC), hormone-refractory prostate cancer (HRPC), and non-small cell lung cancer (NSCLC).

Brand names: Breceptin

Targets

Bradykinin B2 receptorBDKRB1 (Bradykinin Receptor B1)

Beyond the preview

Go deeper on B201 acetate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on B201 acetate.

Explore the full profile